|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray.
|
16481301 |
2006 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although it is well known that CDKN2A mutations confer an increased risk for melanoma and pancreatic carcinoma, the association with an increased risk for nerve sheath tumours and other tumour types is under-recognized.
|
26876133 |
2016 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Some CDKN2A mutations have been associated not only with melanoma but also with increased risk of other malignancies--most notably pancreatic carcinoma.
|
20687502 |
2010 |
|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of p16(INK4a) induces either cell cycle arrest or apoptosis in different pancreatic cancer cell lines.
|
15309028 |
2004 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using LD-PCR, mutations in p53 and/or p16 were found in the pancreatic juice of 12 of 20 individuals with pancreatic cancer compared to only 1 of 8 patients with chronic pancreatitis, 0 of 8 individuals without evidence of pancreatic disease (p<0.02).
|
17106238 |
2006 |
|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancreatitis and in 63% of pancreas cancer cell lines.
|
12802288 |
2003 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we observed a novel association in a pleiotropic region that has been found to be of key relevance in the susceptibility to various types of cancer and diabetes suggesting that the CDKN2A/B locus could represent a genetic link between diabetes and pancreatic cancer risk.
|
27486979 |
2016 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between INK4/ARF alterations and the occurrence of pancreatic cancer in MF and in sporadic pancreatic cancer (SPC) patients.
|
14679123 |
2004 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The p16-Leiden germline variant in the CDKN2A gene is associated with a high risk of melanoma and pancreatic cancer.
|
25227142 |
2015 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is also an increased risk of pancreatic cancer in a subset of families with mutations, however, the precise relationship between the CDKN2A gene and pancreatic cancer remains unknown.
|
15146471 |
2004 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alterations in the ARF tumor suppressor protein (also known as p14ARF in humans and p19ARF in the mouse) occur frequently in cancer and are associated with susceptibility to melanoma, pancreatic cancer and nervous system tumors.
|
17630509 |
2007 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CDKN2A mutation carriers were more likely to have a family history of pancreatic cancer (P=0.003) or melanoma (P=0.03), and a personal history of melanoma (P=0.01).
|
21150883 |
2011 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.
|
22806240 |
2013 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequency of somatic TP53 and p16INK4a mutations in pancreatic cancer is similar in patients with and without multiple primaries.
|
11075991 |
2000 |
|
Pancreatic carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Because aberrant methylation of ppENK or p16 was more often detected in similar grade PanINs from patients with pancreatic carcinoma than in those with other pancreatic diseases, it may be a useful indicator of the potential malignancy of epithelial cells of the pancreas.
|
12000709 |
2002 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results strongly suggest that CDKN2A methylation is correlated with an increased risk of pancreatic cancer.
|
26338139 |
2015 |
|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Tumor suppressor p16INK4a--modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells.
|
17535296 |
2007 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice.
|
11948142 |
2002 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we show that in an area with low melanoma incidence, CDKN2A germline mutations in patients with melanoma and personal or family history of pancreatic cancer are mainly present in the setting of familial or multiple melanoma cases.
|
29543703 |
2018 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To verify the S305N association with melanoma risk in an independent larger French population (378 patients, 389 controls); to investigate the role of EDNRB variants in melanoma risk in an Italian population (133 patients, 118 controls); and to explore the association of CDKN2A or CDK4 mutations with the S305N EDNRB variant in a subgroup of patients (59 French, 12 Italian) with a suspected hereditary predisposition to melanoma (familial melanoma, sporadic multiple primary melanoma or melanoma associated with pancreatic cancer).
|
21507037 |
2011 |
|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
|
16127777 |
2005 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have tested nanopore sequencing to detect a series of well-characterized SVs, including large deletions, inversions, and translocations that inactivate the CDKN2A/p16 and SMAD4/DPC4 tumor suppressor genes in pancreatic cancer.
|
26787508 |
2016 |
|
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The incidence of p16 mutations was 2 (9%) in 22 cases of pancreatic carcinoma with strongly positive staining, 4 (17%) in 24 with weakly positive staining, and 3 (21%) in 14 with negative staining.
|
12898359 |
2003 |
|
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study shows for the first time that p16(INK4a) alterations can be observed in a considerable number of PanIN1 in chronic pancreatitis tissues not associated with pancreatic cancer.
|
11283541 |
2001 |
|
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer.
|
22213426 |
2012 |